T
Thomas H. Oliphant
Researcher at Pharmacia
Publications - 4
Citations - 887
Thomas H. Oliphant is an academic researcher from Pharmacia. The author has contributed to research in topics: Linezolid & Tolerability. The author has an hindex of 4, co-authored 4 publications receiving 859 citations.
Papers
More filters
Journal ArticleDOI
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.
TL;DR: Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia and Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups.
Journal ArticleDOI
Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia
TL;DR: In the population studied, linezolid appeared to be as well tolerated and as effective as vancomycin, each in combination with aztreonam.
Journal ArticleDOI
Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies
Ethan Rubinstein,Raul E Isturiz,Harold C. Standiford,Leon G. Smith,Thomas H. Oliphant,Sue Cammarata,Barry Hafkin,Vu Le,Jack S. Remington +8 more
TL;DR: The risk for transient, reversible hematologic effects from treatment with linezolid should be considered together with the clinical benefits associated with its use.
Journal ArticleDOI
Linezolid Versus Ceftriaxone/Cefpodoxime in Patients Hospitalized for the Treatment of Streptococcus pneumoniae Pneumonia
TL;DR: Empiric i.v./oral linezolid was more effective than ceftriaxone/cefpodoxime in patients hospitalized with CAP, with comparable cure rates in S. pneumoniae pneumonia and higher cure rate in pneumonia complicated by bacteremia.